Non-Muscle Invasive Bladder Cancer Pipeline Insights | Clinical Trials Report 2022 by DelveInsight
January 31, 2022 13:00 ET
|
DelveInsight Business Research LLP
Las Vegas, USA, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Non-Muscle Invasive Bladder Cancer Pipeline Insights | Clinical Trials Report 2022 by DelveInsight Non-Muscle Invasive Bladder Cancer Pipeline...
Worldwide Immuno Oncology Assays Industry to 2026 - Clinical Trials to Cure Different Cancers in Immunotherapy Presents Opportunities
January 05, 2022 06:38 ET
|
Research and Markets
Dublin, Jan. 05, 2022 (GLOBE NEWSWIRE) -- The "Immuno Oncology Assays Market Research Report by Indication, Product, Technology, Application, and Region - Global Forecast to 2026 - Cumulative Impact...
First Patient Dosed in Study of Targeted Alpha Therapy Candidate for Bladder Cancer
December 20, 2021 16:45 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and NANTES, France, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) and Nantes-based ATONCO S.A.S. (‘ATONCO’) today announce that...
Theralase Expands Intellectual Property Portfolio
December 09, 2021 07:00 ET
|
Theralase Technologies Inc.
TORONTO, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research...
Aprea Therapeutics to Present Data from Phase 1/2 Trial of Eprenetapopt in Advanced Solid Tumors at ESMO Congress 2021
September 14, 2021 08:00 ET
|
Aprea Therapeutics
BOSTON, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate...
Theralase Releases Q221 Unaudited Financial Statements and Quarterly Newsletter
August 30, 2021 18:15 ET
|
Theralase Technologies Inc.
TORONTO, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), A clinical stage pharmaceutical company dedicated to the research...
Imagin Medical on Schedule for American Urology Association Demonstration
August 17, 2021 08:30 ET
|
Imagin Medical Inc.
VANCOUVER, British Columbia, and BOSTON, Aug. 17, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (“Imagin” or the...
First Patient Dosed in Clinical Study of TLX250-CDx in Bladder Cancer
June 22, 2021 19:22 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia, June 22, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces that a first patient has been dosed in a Phase I study of...
Theralase® Launches Seventh US-Based Clinical Study Site and Treats First Patient in the US
June 11, 2021 07:00 ET
|
Theralase Technologies Inc.
TORONTO, June 11, 2021 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research...
Theralase Releases Q12021 Interim Financial Statements
May 28, 2021 18:58 ET
|
Theralase Technologies Inc.
TORONTO, May 28, 2021 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research...